Eli Lilly and Company (LLY)

[johnsyn]

1:59 PM Eli Lilly (LLY +2.6%) pops after a new study shows its experimental Alzheimer’s treatment slowed memory loss and cognitive decline in early-stage patients by ~30%, offering the first evidence that a medication may hamper the course of the ailment. The independent analysis supports LLY’s August report that showed the drug, solanezumab, slowed mental decline in those with mild Alzheimer’s